BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15287917)

  • 21. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study.
    Fujiwara D; Hino K; Yamaguchi Y; Kubo Y; Yamashita S; Uchida K; Konishi T; Nakamura H; Korenaga M; Okuda M; Okita K
    J Viral Hepat; 2004 Mar; 11(2):136-40. PubMed ID: 14996348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-translational up-regulation of the cell surface-associated alpha component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon.
    Eantuzzi L; Eid P; Malorni W; Rainaldi G; Gauzzi MC; Pellegrini S; Belardelli F; Gessani S
    Eur J Immunol; 1997 May; 27(5):1075-81. PubMed ID: 9174595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro inducing differentiation of bone marrow mononuclear cells of chronic myeloid leukemia].
    Wu CY; Zhang LS; Zhang YF; Chai Y; Yi LC; Song FX
    Ai Zheng; 2005 Apr; 24(4):425-31. PubMed ID: 15820064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
    Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
    Bremer CT; Lastrapes A; Alper AB; Mudad R
    Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of T-cell receptor beta chain mRNA expression in IFN-alpha-responsive chronic myelogenous leukaemia patients.
    Shimomura T; Fujii S; Ezaki I; Osato M; Fujimoto K; Takatsuki K; Yamamoto K; Kawakita M
    Br J Haematol; 1999 Apr; 105(1):173-80. PubMed ID: 10233381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.
    Cornelissen JJ; Ploemacher RE; Wognum BW; Borsboom A; Kluin-Nelemans HC; Hagemeijer A; Löwenberg B
    J Clin Invest; 1998 Sep; 102(5):976-83. PubMed ID: 9727066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
    Lamken P; Lata S; Gavutis M; Piehler J
    J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.
    Kondo M; Nagano H; Sakon M; Yamamoto H; Morimoto O; Arai I; Miyamoto A; Eguchi H; Dono K; Nakamori S; Umeshita K; Wakasa K; Ohmoto Y; Monden M
    Int J Oncol; 2000 Jul; 17(1):83-8. PubMed ID: 10853022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of G-CSF on the proliferation and differentiation of bcr/abl(+)-CD34+ cells from CML patients].
    Li CY; Meng FY; Sun QX; Fu YB; Jiang QL; Yi ZS; Song LL
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):762-5. PubMed ID: 18457269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia modifies proliferation and differentiation of CD34(+) CML cells.
    Desplat V; Faucher JL; Mahon FX; Dello Sbarba P; Praloran V; Ivanovic Z
    Stem Cells; 2002; 20(4):347-54. PubMed ID: 12110704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
    Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.
    Kumar KG; Tang W; Ravindranath AK; Clark WA; Croze E; Fuchs SY
    EMBO J; 2003 Oct; 22(20):5480-90. PubMed ID: 14532120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.